Literature DB >> 33772465

Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity.

Vanessa Pereira1,2, Sylvain Lamoine1,2, Mélissa Cuménal1,2, Stéphane Lolignier1,2, Youssef Aissouni1,2, Anne Pizzoccaro3, Laetitia Prival1,2, David Balayssac1,2, Alain Eschalier1,2, Emmanuel Bourinet3, Jérôme Busserolles4,5.   

Abstract

Peripheral neuropathy is the most frequent dose-limiting adverse effect of oxaliplatin. Acute pain symptoms that are induced or exacerbated by cold occur in almost all patients immediately following the first infusions. Evidence has shown that oxaliplatin causes ion channel expression modulations in dorsal root ganglia neurons, which are thought to contribute to peripheral hypersensitivity. Most dysregulated genes encode ion channels involved in cold and mechanical perception, noteworthy members of a sub-group of potassium channels of the K2P family, TREK and TRAAK. Downregulation of these K2P channels has been identified as an important tuner of acute oxaliplatin-induced hypersensitivity. We investigated the molecular mechanisms underlying this peripheral dysregulation in a murine model of neuropathic pain triggered by a single oxaliplatin administration. We found that oxaliplatin-mediated TREK-TRAAK downregulation, as well as downregulation of other K+ channels of the K2P and Kv families, involves a transcription factor known as the neuron-restrictive silencer factor (NRSF) and its epigenetic co-repressors histone deacetylases (HDACs). NRSF knockdown was able to prevent most of these K+ channel mRNA downregulation in mice dorsal root ganglion neurons as well as oxaliplatin-induced acute cold and mechanical hypersensitivity. Interestingly, pharmacological inhibition of class I HDAC reproduces the antinociceptive effects of NRSF knockdown and leads to an increased K+ channel expression in oxaliplatin-treated mice.

Entities:  

Keywords:  HDAC; NRSF; Neuropathic pain; Oxaliplatin; Potassium channels

Mesh:

Substances:

Year:  2021        PMID: 33772465     DOI: 10.1007/s12035-021-02361-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  76 in total

Review 1.  Oxaliplatin-associated neuropathy: a review.

Authors:  Robert J Cersosimo
Journal:  Ann Pharmacother       Date:  2004-12-08       Impact factor: 3.154

Review 2.  Oxaliplatin-related neurotoxicity: how and why?

Authors:  Lara Maria Pasetto; Mario Rosario D'Andrea; Elena Rossi; Silvio Monfardini
Journal:  Crit Rev Oncol Hematol       Date:  2006-06-27       Impact factor: 6.312

3.  Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.

Authors:  Alberto Pietrangeli; Massimo Leandri; Edmondo Terzoli; Bruno Jandolo; Carlo Garufi
Journal:  Eur Neurol       Date:  2006-07-03       Impact factor: 1.710

4.  Oxaliplatin-induced neurotoxicity and the development of neuropathy.

Authors:  Arun V Krishnan; David Goldstein; Michael Friedlander; Matthew C Kiernan
Journal:  Muscle Nerve       Date:  2005-07       Impact factor: 3.217

5.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

Authors:  Susanna B Park; Cindy S Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan
Journal:  Oncologist       Date:  2011-04-08

7.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Authors:  Stephanie R Land; Jacek A Kopec; Reena S Cecchini; Patricia A Ganz; H Samuel Wieand; Linda H Colangelo; Kate Murphy; J Philip Kuebler; Thomas E Seay; Burton M Needles; James D Bearden; Lauren K Colman; Keith S Lanier; Eduardo R Pajon; David Cella; Roy E Smith; Michael J O'Connell; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

Review 8.  A review on oxaliplatin-induced peripheral nerve damage.

Authors:  Andreas A Argyriou; Panagiotis Polychronopoulos; Gregoris Iconomou; Elisabeth Chroni; Haralabos P Kalofonos
Journal:  Cancer Treat Rev       Date:  2008-02-20       Impact factor: 12.111

9.  Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.

Authors:  N Attal; D Bouhassira; M Gautron; J N Vaillant; E Mitry; C Lepère; P Rougier; F Guirimand
Journal:  Pain       Date:  2009-05-19       Impact factor: 6.961

10.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  3 in total

1.  The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.

Authors:  Sylvain Lamoine; Mélissa Cumenal; David A Barriere; Vanessa Pereira; Mathilde Fereyrolles; Laëtitia Prival; Julie Barbier; Ludivine Boudieu; Emilie Brasset; Benjamin Bertin; Yoan Renaud; Elisabeth Miot-Noirault; Marie-Ange Civiale; David Balayssac; Youssef Aissouni; Alain Eschalier; Jérôme Busserolles
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Authors:  Kevin P Cunningham; Lucie H Clapp; Alistair Mathie; Emma L Veale
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

3.  Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.

Authors:  Hichem Bouchenaki; Aurore Danigo; Amandine Bernard; Flavien Bessaguet; Laurence Richard; Franck Sturtz; David Balayssac; Laurent Magy; Claire Demiot
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.